TOREMIFENE

Female Breast Carcinoma

Peking Union Medical College HospitalSmall moleculePhase 4 / ApprovedDormant

BB

65/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 50/ 100
Competitive Position: 95/ 100

Competitive context

8 Active assets in the Female Breast Carcinoma cohort.

Asset / Sponsor	Phase	Rating
ANASTROZOLE Ahon Pharmaceutical Co., Ltd.	Phase 4	BBB
PROPOFOL Tata Memorial Centre	Phase 4	BB
Sevoflurane Tata Memorial Centre	Phase 4	BB
Goserelin Ahon Pharmaceutical Co., Ltd.	Phase 3	BB
FULVESTRANT Ahon Pharmaceutical Co., Ltd.	Phase 3	BB

View all 21 →

Same molecule, other indications

TOREMIFENE is also rated in:

prostate intraepithelial neoplasiaDormant

BB

Indicative · Phase 3

68 / 100

breast carcinoma in situDormant

BB

Indicative · Phase 4

65 / 100

invasive breast carcinomaDormant

BB

Indicative · Phase 4

65 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.